Tel-Aide Montréal Launches Toll-Free Number and Expands its Service for English-Speaking Quebecers
MONTREAL, May 1, 2025 /CNW/ - One in five Quebecers struggles with mental health issues, yet many don't know where to turn, especially English-speaking Quebecers, who often face limited access to resources in their language. To improve accessibility, Tel-Aide Montréal (TAM) is expanding its free, confidential, and anonymous active listening service to be available 24/7 across Quebec, thanks to a new toll-free number: 1 877 935-1101. English-speaking individuals can now access a listening ear anytime, from anywhere in the province.
"For over 50 years, Tel-Aide Montréal has offered a safe and compassionate space for people to be heard—without judgment—in both English and French in the Greater Montreal area," said Sandra Di Quinzio, Interim Executive Director. "With this new toll-free number, we're extending that support to the entire province. No matter where you are in Quebec, someone is here to listen. Because everyone deserves to be heard."
This initiative is made possible thanks to funding from the Secrétariat aux relations avec les Québécois d'expression anglaise (SRQEA) of $660,000 over the next two years. "Everyone should have someone to talk to when they need support; day or night," said Minister Eric Girard. "We're proud to partner with Tel-Aide Montréal to strengthen mental health services for English-speaking Quebecers."
A Step Forward for Mental Health Support in Quebec
Following a volunteer shortage in 2022, TAM was forced to suspend overnight service. Today, that service is not only reinstated; it's expanded province-wide, powered by over 170 trained volunteers and a dedicated team of employees offering active listening around the clock.
Who Can Call Tel-Aide Montréal?
Anyone feeling lonely, overwhelmed, or in need of a listening ear can reach out. Whether it's stress, isolation, or a difficult moment, no issue is too small—TAM is here to listen.
Montreal area: 514 935-1101
Toll-free, province-wide: 1 877 935-1101
About Tel-Aide Montréal
TAM offers empathetic active listening services in both English and French, creating a safe and respectful space – free of advice, judgment or interruption — for anyone in need of a listening ear. This approach helps reduce stress, fosters understanding, and offers comfort in difficult moments, reminding callers they are not alone.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
13 hours ago
- Cision Canada
OXLUMO® (lumasiran injection) Now Reimbursed in Canada For the Treatment of Primary Hyperoxaluria Type 1 (PH1) in Pediatric and Adult Patients
OXLUMO has been shown to significantly reduce urinary oxalate, which drives the progression of PH1 Disease 1 MISSISSAUGA, ON, July 2, 2025 /CNW/ - Alnylam Canada ULC is pleased to announce that OXLUMO ® (lumasiran) is now funded across Canada through both public and private plans. OXLUMO is an RNA interference (RNAi) therapeutic administered via subcutaneous injection, indicated for the treatment of primary hyperoxaluria type 1 (PH1) to lower urinary oxalate levels in paediatric and adult patients. 1 OXLUMO is the first therapy for PH1 approved in Canada, and among the first medications to be included on the common list of new drugs for rare diseases, as part of the Government of Canada's National Strategy for Drugs for Rare Diseases. The common list was developed to help patients with rare diseases have access to treatments as early as possible. PH1 is an ultra-rare and debilitating genetic disease of the liver characterized by oxalate overproduction. 2 Oxalate is an end-product of metabolism and high levels of it are toxic because it cannot be broken down by the human body. Oxalate overproduction results in the deposition of calcium oxalate crystals in the kidneys and urinary tract and can lead to the formation of painful and recurrent kidney stones, nephrocalcinosis (renal deposition of calcium oxalate crystals), progression to kidney failure, and systemic organ dysfunction. 2 "Funding OXLUMO through the National Strategy for Drugs for Rare Diseases provides a new treatment option for people diagnosed with this debilitating, genetic disease – many of whom are infants and children," said Colleen Coxson, Country General Manager, Alnylam Canada ULC. "I want to congratulate the Canadian government for prioritizing access to therapies for those living with rare conditions, as there are often very limited options for patients." There are several types of primary hyperoxaluria (PH), however, PH1 is the most common and the most severe form, accounting for 70 to 80 per cent of all PH cases. 3 PH1 affects approximately four individuals per million, with some regions – such as the Middle East and North Africa – having a higher genetic prevalence. 4 Symptom onset ranges from early infancy to sixty years of age, with the median age being four to six years. 4 The remainder of affected cases present in adulthood with 20 to 50 per cent presenting late stages of chronic kidney disease when diagnosed. 4 "This funding decision marks a major step forward in the management of hyperoxaluria type 1, offering hope to patients of all ages living with this ultra-rare genetic condition," said Dr. Vladimir Belostotsky, Division Head for Pediatric Nephrology at McMaster Children's Hospital. "The medication has been shown to effectively lower urine oxalate levels, reducing the burden that leads to severe clinical symptoms." The positive recommendation for reimbursement was supported by results of the ILLUMINATE clinical studies, including ILLUMINATE-A: a randomized, double-blind, placebo-controlled clinical study in patients six years and older with PH1, ILLUMINATE-B: a single-arm clinical study in patients less than six years of age with PH1 1 and ILLUMINATE-C: a single-arm trial in patients of all ages with advanced PH1, including patients on dialysis. 5 The ILLUMINATE-A study showed that OXLUMO met its primary endpoint, evidenced by a 53 per cent mean reduction in urinary oxalate, and a 65 per cent mean reduction in urinary oxalate relative to baseline. 1 In ILLUMINATE-B, OXLUMO demonstrated a 72 per cent mean reduction in spot urinary oxalate:creatinine ratio from baseline to month six (averaged from months three to six), meeting its primary endpoint. 1 In ILLUMINATE-C, OXLUMO met its primary endpoint, demonstrating a 33% least squares (LS) mean reduction in plasma oxalate (POx) levels in patients not on dialysis (Cohort A) and a 42% LS mean reduction in POx levels in patients on hemodialysis (Cohort B) from baseline to month six. 6 About OXLUMO ® (lumasiran) 1 OXLUMO ® (lumasiran) is an RNAi therapeutic targeting hydroxyacid oxidase 1 (HAO1) in the liver to deplete the production of the glycolate oxidase (GO) enzyme. By silencing HAO1 and depleting the GO enzyme through RNA interference, OXLUMO in turn reduces the amount of oxalate that is produced. This process helps address the root cause of the rare, genetic disease since an overproduction of urinary and plasma oxalate levels is the underlying cause of PH1. About Primary Hyperoxaluria Type 1 (PH1) PH1 is an ultra-rare genetic disease that is characterized by oxalate overproduction in the liver, causing renal damage. Renal damage is caused by a combination of tubular toxicity from oxalate, calcium oxalate deposition in the kidneys, and urinary obstruction by calcium oxalate stones. PH1 is associated with a progressive decline in kidney function, which exacerbates the disease as the excess oxalate can no longer be effectively excreted, resulting in subsequent accumulation and deposition of oxalate in bones, eyes, skin, and heart, leading to severe illness and death. Management options to date have been limited to hyperhydration, crystallization inhibitors and, in a minority of patients with a specific genotype, pyridoxine (vitamin B6). These measures only delay the inevitable progression to kidney failure and the need for intensive dialysis as a bridge to a dual or sequential liver/kidney transplant. Other impacts of the disease include: infants often fail to thrive, meaning they are weak and not growing or developing at a normal rate. 7 Affected children frequently face developmental challenges, with social barriers and the requirement of accommodations to be made at school to meet their special medical needs. 6 About RNAi RNAi (RNA interference) is a natural cellular process of gene silencing that represents one of the most promising and rapidly advancing frontiers in biology and drug development today. Its discovery has been heralded as "a major scientific breakthrough that happens once every decade or so," and was recognized with the award of the 2006 Nobel Prize for Physiology or Medicine. By harnessing the natural biological process of RNAi occurring in our cells, a new class of medicines known as RNAi therapeutics is now a reality. Small interfering RNA (siRNA), the molecules that mediate RNAi and comprise Alnylam's RNAi therapeutic platform, function upstream of today's medicines by potently silencing messenger RNA (mRNA) – the genetic precursors that encode for disease-causing or disease pathway proteins – thus preventing them from being made.5 This is a revolutionary approach with the potential to transform the care of patients with genetic and other diseases. About Alnylam Pharmaceuticals Alnylam (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and prevalent diseases with unmet need. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach yielding transformative medicines. Since its founding in 2002, Alnylam has led the RNAi Revolution and continues to deliver on a bold vision to turn scientific possibility into reality. Alnylam has a deep pipeline of investigational medicines, including multiple product candidates that are in late-stage development. Alnylam is executing on its " Alnylam P 5 x25" strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile. Alnylam is headquartered in Cambridge, MA. Alnylam Canada is headquartered in Mississauga, Ontario with established operations since June 2018.
Cision Canada
15 hours ago
- Cision Canada
Apotex receives Health Canada approval for Aflivu™, a biosimilar to Eylea®, available in pre-filled syringe and vial formats
TORONTO, July 2, 2025 /CNW/ - Apotex Inc. ("Apotex" or the "Company"), the Canadian-based global health company, today announced that Health Canada has approved Aflivu™ (aflibercept), a biosimilar to Eylea®, indicated for the treatment of neovascular (wet) age-related macular degeneration, macular edema secondary to central or branch retinal vein occlusion, treatment of diabetic macular edema, and treatment of myopic choroidal neovascularization. This approval marks a key milestone for Apotex, introducing its first ophthalmic biosimilar and its fourth biosimilar since 2016, and reflecting the Company's commitment to expand its biologics portfolio and execution of its Journey of Health strategy. "With Aflivu, we're expanding affordable treatment options for Canadians affected by retinal diseases," said Raymond Shelley, President, Apotex Canada. "Apotex continues to deliver innovative, patient-focused solutions across our growing portfolio of brands, biosimilars, generics and consumer health products." "The approval of Aflivu represents a positive advancement in ophthalmic care," said Dr. Bernard R. Hurley, BSc, MD, FRCSC, Assistant Professor at the University of Ottawa Eye Institute. "Biosimilars, supported by clinicians, regulators, and manufacturers, have the potential to transform the treatment landscape for retinal diseases, preserving vision and providing quality, cost-effective care for countless Canadians." "In clinical practice, having access to a broader range of therapeutic options can empower physicians to tailor care to individual patients' needs," said Dr. Ghassan Cordahi, MD, FACS, Assistant Clinical Professor, Faculty of Medicine, Department of Ophthalmology, Université de Montréal. "Aflibercept has been a cornerstone in managing retinal diseases, and the introduction of Aflivu offers a more affordable alternative without compromising quality." Aflivu joins Apotex's successful biosimilar portfolio, which includes Grastofil® (filgrastim), Lapelga® (pegfilgrastim), and Bambevi® (bevacizumab). About Apotex Apotex is a Canadian-based global health company. We improve everyday access to affordable, innovative medicines and health products for millions of people around the world, with a broad portfolio of generic, biosimilar, and innovative branded pharmaceuticals, and consumer health products. Headquartered in Toronto, with regional offices globally, including in the United States, Mexico, and India, we are the largest Canadian-based pharmaceutical company and a health partner of choice for the Americas for pharmaceutical licensing and product acquisitions.
Canada News.Net
16 hours ago
- Canada News.Net
France cracks down on public smoking to protect children
PARIS, France: France is taking stronger steps to reduce smoking. A new health rule announced on Saturday will soon ban smoking in many public places. This includes all parks, beaches, sports areas, bus stops, and near schools—anywhere children might be present. Smoking has long been seen as a part of French culture, especially in films. Because of this, government efforts to limit smoking have often faced pushback. Philippe Bergerot, head of the French League Against Cancer, said that some people still see smoking bans as limiting their freedom. But he explained that the goal is to make smoking seem less normal in public life. "We are not banning smoking completely," he said. "We are just banning it in places where it can harm others, especially young people." France already banned smoking inside restaurants, bars, and public buildings in 2007 and 2008. Cigarette prices have also gone up sharply due to taxes, with a pack now costing over 12 euros (around $14). Still, over 30% of French adults smoke, most of them every day. That's one of the highest rates in Europe and the world. Officials are apprehensive about young people—about 15% of 17-year-olds smoke, and illegal cigarette sales are common. Health Minister Catherine Vautrin said tobacco causes about 200 deaths every day in France, or 75,000 each year. Some people support the new rules, while others feel they go too far. In a park in Paris, a woman named Natacha Uzan said she agreed with the ban in restaurants, but thought banning smoking in parks was "a bit too much." Another woman, Anabelle Cermell, who has a baby, welcomed the rule. "It's not ideal when people smoke around my child," she said, "but before this, there wasn't much I could do." The government said the ban will start on July 1. It will soon share more details about exactly where it applies. Other European countries are also taking more decisive actions. Britain and Sweden have stricter public smoking rules. Spain is expanding its ban to include café and restaurant terraces, which are still allowed under France's new rules.
